Pasar al contenido principal

IMPACTO DE LA INTERRELACION FUNCIONAL ENTRE GSDMB Y GSDMD EN LA CARCINOGENESIS, PROGRESION TUMORAL Y RESPUESTA TERAPEUTICA EN CANCER DE MAMA HER2

PID2022-136854OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer, towards the clinical application

  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Vilar, Ana
  • Cueva, Juan|||0000-0003-1389-4595
  • Arias, Efigenia
  • Sampayo, Victoria
  • Diaz, Eva
  • Oltra, Sara S.
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Cortegoso, Alexandra
  • Curiel, Teresa
  • Abalo, Alicia
  • Pamies Serrano, Mónica
  • Domingo, Santiago
  • Padilla-Iserte, Pablo
  • Arnaez de la Cruz, Marta
  • Hernández Gutierrez, Alicia|||0000-0002-2494-3041
  • García-Pineda, Virginia
  • Ruiz-Bañobre, Juan
  • López, Rafael
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined. This study was designed to determine the value of cfDNA/ctDNA monitoring in improving the clinical management of patients with localized and recurrent disease. Plasma samples and uterine aspirates (UA) from 198 EC patients were collected at surgery and over time. The genetic landscape of UAs was characterized using targeted sequencing. Total cfDNA was analyzed for ctDNA presence based on the UA mutational profile. High cfDNA levels and detectable ctDNA at baseline correlated with poor prognosis for DFS (p-value < 0.0001; HR = 9.25) and DSS (p-value < 0.0001; HR = 11.20). This remained clinically significant when stratifying tumors by histopathological risk factors. Of note, cfDNA/ctDNA analyses discriminated patients with early post-surgery relapse and the ctDNA kinetics served to identify patients undergoing relapse before any clinical evidence emerged. This is the most comprehensive study on cfDNA/ctDNA characterization in EC, demonstrating its value in improving risk stratification and anticipating disease relapse in patients with localized disease. CtDNA kinetics assessment complements current strategies to monitor the disease evolution and the treatment response. Therefore, implementing cfDNA/ctDNA monitoring in clinical routines offers a unique opportunity to improve EC management. The study demonstrates that high levels of cfDNA and detectable ctDNA at baseline are strong indicators of poor prognosis. This enables more accurate risk stratification beyond traditional histopathological factors, allowing clinicians to identify high-risk patients who may benefit from more aggressive treatment and closer monitoring. Moreover, longitudinal analysis of cfDNA/ctDNA can detect disease recurrence months before clinical symptoms or imaging evidence appear. This early warning system offers a significant advantage in clinical practice, providing a window of opportunity for early intervention and potentially improving patient outcomes. The online version contains supplementary material available at 10.1186/s13046-024-03158-w.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling

  • Marugan, Carlos
  • Sanz-Gómez, Natalia
  • Ortigosa, Beatriz
  • Monfort-Vengut, Ana
  • Bertinetti, Cristina
  • Teijo, Ana
  • González, Marta
  • Alonso, Alicia
  • Lallena, María José
  • Moreno-Bueno, Gema
  • Cárcer, Guillermo de
Chromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allows the tumor to evolve and adapt to stress conditions. CIN is considered a cancer therapeutic biomarker because healthy cells do not exhibit CIN. Despite recent efforts to identify therapeutic strategies related to CIN, the results obtained have been very limited. CIN is characterized by a genetic signature where a collection of genes, mostly mitotic regulators, are overexpressed in CIN-positive tumors, providing aggressiveness and poor prognosis. We attempted to identify new therapeutic strategies related to CIN genes by performing a drug screen, using cells that individually express CIN-associated genes in an inducible manner. We find that the overexpression of targeting protein for Xklp2 (TPX2) enhances sensitivity to the proto-oncogene c-Src (SRC) inhibitor dasatinib due to activation of the Yes-associated protein 1 (YAP) pathway. Furthermore, using breast cancer data from The Cancer Genome Atlas (TCGA) and a cohort of cancer-derived patient samples, we find that both TPX2 overexpression and YAP activation are present in a significant percentage of cancer tumor samples and are associated with poor prognosis; therefore, they are putative biomarkers for selection for dasatinib therapy., This study has been supported by the following grants: From the “Ministerio de Ciencia, Innovación, Agencia Estatal de Investigación MCIN/AEI/FEDER” (http://doi.org/10.13039/501100011033): RTI2018-095496-B-I00 and PID2021-125705OB-I00 (GdC); PID2019-104644RB-I00 & PID2022-136854OB-I00 (GM-B); Juan de la Cierva Postdoctoral program FJC2020-044620-I (NS-G). From the Spanish Association Against Cancer (AECC) Scientific Foundation: LABAE16017DECA (GdC); PROYE19036MOR (GMB); POSTD234371SANZ (NS-G). From the Spanish National Research Council (CSIC): 2018-20I114, 2021-AEP035, and 2022-20I018 (GdC). From the Instituto de Salud Carlos III – CIBERONC: CB16/12/00295 (GM-B)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structural and functional insights into GSDMB isoforms complex roles in pathogenesis

  • Colomo, Sara
  • Ros-Pardo, David
  • Oltra, Sara S.
  • Gómez-Puertas, Paulino
  • Sarrió, David
  • Moreno-Bueno, Gema
ABSTRACT SHADS: Gasdermins (GSDMs) have garnered significant scientific interest due to their protective and detrimental roles in innate immunity, host defense, inflammation, and cancer alongside with other pathologies. While GSDMs are mostly recognized as key effectors of a lytic type of pro-inflammatory cell death known as pyroptosis, they do also take part in other cell death processes (NETosis, secondary necrosis, or apoptosis) and exhibit cell-death independent functions depending on the cellular context. Among GSDMs, Gasdermin B (GSDMB) pyroptotic capacity has been a subject of conflicting findings in scientific literature even when its processing, and subsequent activation, by Granzyme A (GZMA) was decoded. Nevertheless, recent groundbreaking publications have shed light on the crucial role of alternative splicing in determining the pyroptotic capacity of GSDMB isoforms, which depends on the presence of exon 6-derived elements. This comprehensive review pays attention to the relevant structural differences among recently crystalized GSDMB isoforms. As a novelty, the structural aspects governing GSDMB isoform susceptibility to GZMA-mediated activation have been investigated. By elucidating the complex roles of GSDMB isoforms, this review aims to deepen the understanding of this multifunctional player and its potential implications in disease pathogenesis and therapeutic interventions. (Figure presented.)., This study was financed by the following grants: Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (MICINN-AEI, PID2019-104644RB-I00, PDC2022-133252-I00, PID2022-136854OB-I00), the Instituto de Salud Carlos III (CIBERONC, CB16/12/00295), AC21_2/00020 ERA PerMed ERA-NET (cofunded by NextGenerationEU) and the AECC Scientific Foundation (FCAECC PROYE19036MOR and GCTRA18014MATI). DS contract is financed by CIBERONC (partly supported by FEDER funds). SC is funded by the MICINN-AEI PRE2020-095658, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application

  • Casas-Arozamena, Carlos
  • Vilar, Ana
  • Cueva, Juan
  • Arias, Efigenia
  • Sampayo, Victoria
  • Díaz, Eva
  • Oltra, Sara S.
  • Moiola, Cristian P.
  • Cabrera, Silvia
  • Cortegoso, Alexandra
  • Curiel, Teresa
  • Abalo, Alicia
  • Pamies Serrano, Mónica
  • Domingo, Santiago
  • Padilla-Iserte, Pablo
  • Arnaez de la Cruz, Marta
  • Hernández, Alicia
  • García-Pineda, Virginia
  • Ruiz-Bañobre, Juan
  • López, Rafael
  • Matías-Guiu, Xavier
  • Colas, Eva
  • Gil-Moreno, Antonio
  • Abal, Miguel
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura
[Background]: There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined. This study was designed to determine the value of cfDNA/ctDNA monitoring in improving the clinical management of patients with localized and recurrent disease., [Methods]: Plasma samples and uterine aspirates (UA) from 198 EC patients were collected at surgery and over time. The genetic landscape of UAs was characterized using targeted sequencing. Total cfDNA was analyzed for ctDNA presence based on the UA mutational profile., [Results]: High cfDNA levels and detectable ctDNA at baseline correlated with poor prognosis for DFS (p-value < 0.0001; HR = 9.25) and DSS (p-value < 0.0001; HR = 11.20). This remained clinically significant when stratifying tumors by histopathological risk factors. Of note, cfDNA/ctDNA analyses discriminated patients with early post-surgery relapse and the ctDNA kinetics served to identify patients undergoing relapse before any clinical evidence emerged., [Conclusions]: This is the most comprehensive study on cfDNA/ctDNA characterization in EC, demonstrating its value in improving risk stratification and anticipating disease relapse in patients with localized disease. CtDNA kinetics assessment complements current strategies to monitor the disease evolution and the treatment response. Therefore, implementing cfDNA/ctDNA monitoring in clinical routines offers a unique opportunity to improve EC management., This work has been supported by the Instituto de Salud Carlos III (ISCIII) (PI20/00969, PI21/00990 and PI20/01566)/Co-fund by the European Union for A.G-M, M.A and L.M-R; the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (PID2022-136854OB-I00) for G.M-B, the CIBERONC CB16/12/00328 for L.M-R, EC, A.G-M and MA) and CB16/12/00295 for G.M-B) and the Fundación científica AECC through grants for research projects to clinical oncology research coordination groups (GCTRA1804MATI) for A.G-M, MA, X.M-G and G.M-B, Proyectos de Excelencia (IN607D2021/05) for L.M-R and ERA PerMed ERA-NET cofunded by the European Union, NextGeneration-EU through ISCIII and FCAECC (AC21_2/00020) for G.M-B and L.M-R. L.M-R and EC are supported by a contract “Miguel Servet” from ISCIII (CP20/00119, CP22/00147, respectively). SO is funded by an FCAECC-postdoctoral grant (PI21/00990). C.C-A is funded by an IDIS-predoctoral grant (2020). J.R-B is supported by a Juan Rodés contract (JR21/00019) from ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Two distinct epithelial-to-mesenchymal transition programs control invasion and inflammation in segregated tumor cell populations

  • Kass Youssef, Khalil
  • Narwade, Nitin
  • Arcas, Aída
  • Marquez-Galera, Angel
  • Jiménez-Castaño, Raúl
  • López-Blau, Cristina
  • Fazilaty, Hassan
  • García-Gutiérrez, David
  • Cano, Amparo
  • Galcerán, Joan
  • Moreno-Bueno, Gema
  • López-Atalaya, José P.
  • Nieto, M. Ángela
Epithelial-to-mesenchymal transition (EMT) triggers cell plasticity in embryonic development, adult injured tissues and cancer. Combining the analysis of EMT in cell lines, embryonic neural crest and mouse models of renal fibrosis and breast cancer, we find that there is not a cancer-specific EMT program. Instead, cancer cells dedifferentiate and bifurcate into two distinct and segregated cellular trajectories after activating either embryonic-like or adult-like EMTs to drive dissemination or inflammation, respectively. We show that SNAIL1 acts as a pioneer factor in both EMT trajectories, and PRRX1 drives the progression of the embryonic-like invasive trajectory. We also find that the two trajectories are plastic and interdependent, as the abrogation of the EMT invasive trajectory by deleting Prrx1 not only prevents metastasis but also enhances inflammation, increasing the recruitment of antitumor macrophages. Our data unveil an additional role for EMT in orchestrating intratumor heterogeneity, driving the distribution of functions associated with either inflammation or metastatic dissemination., This work was supported by grants MICIU RTI2018-096501-B-I00 and MCI PID2021-125682NB-I00 to M.A.N., RTI2018-102260-B-I00 to J.P.L.-A. and PID2022-136854OB-I00 to G.M.-B., all funded by MICIU/AEI/10.13039/501100011033 and by FEDER; UE Funds were also provided by the AECC Scientific Foundation (FC_AECC PROYE19073NIE to M.A.N. and PROYE19036MOR to G.M.-B.), Instituto de Salud Carlos III (CIBERONC, CB16/12/00295 to G.M.-B. and A.C.; CIBERER, CB19/07/00038 to M.A.N.), Generalitat Valenciana (Prometeo 2021/45) and the European Research Council (ERC AdG 322694) to M.A.N., who also acknowledges financial support from Centro de Excelencia Severo Ochoa, grant CEX2021-001165-S, funded by MCIN/AEI/10.13039/501100011033, and support from the Scientific Network Conexión Cáncer funded by CSIC, Spain. K.K.Y. was a holder of an EMBO Long-Term fellowship and a ‘Severo Ochoa Excellence Program’ Postdoctoral contract and currently holds an investigator contract from the AECC Scientific Foundation (Ayudas AECC investigador 2022). N.N. held a contract associated with NEUcrest European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie (grant agreement 860635, ITN NEUcrest to M.A.N.). R.J.-C. holds a ‘Severo Ochoa Excellence Programme’ PhD contract (PRE2020-091888)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Mamíferos - Roedores, in silico, in vitro - Sistemas de cultivo - Cultivos 2D - Cultivo 2D sin fluídica, in vitro - Sistemas de cultivo - Cultivos 3D, ex vivo
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tumor-Intrinsic Perinuclear LOXL2: Prognostic Relevance and Relationship with YAP1 Activation Status in Oral Squamous Cell Carcinoma

  • Rodrigo, Juan P.
  • Moreno-Bueno, Gema
  • Lequerica-Fernández, Paloma
  • Rodríguez-Santamarta, Tania
  • Díaz, Eva
  • Prieto-Fernández, Llara
  • Álvarez-Teijeiro, Saúl
  • García-Pedrero, Juana M.
  • Vicente, Juan Carlos de
[Introduction]: Lysyl oxidase-like 2 (LOXL2) expression and function is frequently altered in different cancers but scarcely explored in oral squamous cell carcinoma (OSCC). This prompted us to investigate the clinical relevance of LOXL2 expression pattern in OSCC and also a possible crosstalk with Hippo/YAP1 pathway signaling., [Methods]: Immunohistochemical analysis of LOXL2 protein expression was performed in 158 OSCC patient samples, together with Yes-associated protein 1 (YAP1) activation status. Correlations with clinicopathological parameters and patient survival were assessed., [Results]: Tumor cell-intrinsic LOXL2 expression showed two distinct expression patterns: diffuse cytoplasmic staining (64.6%) and heterogeneous perinuclear staining (35.4%). Remarkably, perinuclear LOXL2 staining was significantly associated with lymph node metastasis, advanced clinical stage and perineural invasion. Moreover, patients harboring tumors with perinuclear LOXL2 expression exhibited significantly poorer disease-specific survival (DSS) rates, and perinuclear LOXL2 positivity gradually increased in relation to YAP1 activation. Patients harboring tumors with concomitant perinuclear LOXL2 and fully active YAP1 exhibited the worst DSS. Multivariate Cox analysis further revealed combined perinuclear LOXL2 and fully active YAP1 as a significant independent predictor of poor DSS., [Conclusion]: Tumor-intrinsic perinuclear LOXL2 emerges as a clinically and biologically relevant feature associated with advanced disease, tumor aggressiveness, and poor prognosis in OSCC. Moreover, this study unprecedentedly uncovers a functional relationship between perinuclear LOXL2 and YAP1 activation with major prognostic implications. Notably, combined perinuclear LOXL2 and fully active YAP1 was revealed as independent predictor of poor prognosis. These findings encourage targeting oncogenic LOXL2 functions for personalized treatment regimens., This study was supported by the Instituto de Salud Carlos III (ISCIII, Spain) through the project grants PI19/01255, PI19/00560 and PI22/00167, CIBERONC CB16/12/00390 and CB16/12/00295, and co-funded by the European Union, the Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Fundación Bancaria Caja de Ahorros de Asturias-IUOPA, Universidad de Oviedo, Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (MICINN-AEI, PDC2022-133252-I00, PID2022-136854OB-I00), and AC21_2/00020 ERA PerMed ERA-NET (cofunded by NextGenerationEU). Additional funding was provided through the grant “Ayudas para Grupos de Investigación de Organismos del Principado de Asturias 2021–2023” (IDI/2021/000079), funded by Principado de Asturias (Spain) through FICYT and the FEDER Funding Program from the European Union. LPF is a recipient of a FPU-PhD fellowship from the Spanish Ministry of Education, Spain (FPU20/01588), and SAT is a recipient of a Miguel Servet research contract from ISCIII, Spain (CP23/00101) and co-funded by the European Union., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer

  • Morillo-Huesca, Macarena
  • López-Cepero, Ignacio G.
  • Conesa-Bakkali, Ryan
  • Tomé, Mercedes
  • Watts, Colin
  • Huertas, Pablo
  • Moreno-Bueno, Gema
  • Durán, Raúl V.
  • Martínez-Fábregas, Jonathan
Tumor resistance represents a major challenge in the current oncology landscape. Asparagine endopeptidase (AEP) overexpression correlates with worse prognosis and reduced overall survival in most human solid tumors. However, the underlying mechanisms of the connection between AEP and reduced overall survival in cancer patients remain unclear., Research and publication of this work was funded by the EMERGIA 2021 program (EMERGIA21_00124) from the Consejería de Universidad, Investigación e Innovación, Junta de Andalucía, Spain to J.M-F. J.M-F. was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie programme (101025429), the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (MICINN-AEI, RYC2021-032389), the Consejería de Universidad, Investigación e Innovación under the EMERGIA program (EMC21_00124) Junta de Andalucia, and the VII PPIT of the University of Seville (2023/00000479). RVD and G.M-B were supported by MICINN-AEI and European Regional Development Fund (project PID2021-124251OB-I00 and PID2022-136854OB-I00, respectively). G.M-B was also funded by The Instituto de Salud Carlos III IISCIII, CIBERONC (CB16/12/00295) and ERA PerMed ERA-NET co-funded by the NextGeneration-EU (ISCIII and Fundacion cientifica AECC, AC21_2/00020). PH was supported by R + D + I grant (PID2019-104195G) from the Spanish Ministry of Science and Innovation-Agencia Estatal de Investigación/10.13039/501100011033. CW was supported by a Welcome Trust Programme Grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

  • Rodríguez-Baena, Francisco Javier
  • Marquez-Galera, Angel
  • Ballesteros-Martínez, Pablo
  • Castillo, Alba
  • Díaz, Eva
  • Moreno-Bueno, Gema
  • López-Atalaya, José P.
  • Sánchez-Laorden, Berta
Melanoma is one of the tumor types with the highest risk of brain metastasis. However, the biology of melanoma brain metastasis and the role of the brain immune microenvironment in treatment responses are not yet fully understood. Using preclinical models and single-cell transcriptomics, we have identified a mechanism that enhances antitumor immunity in melanoma brain metastasis. We show that activation of the Rela/Nuclear Factor κB (NF-κB) pathway in microglia promotes melanoma brain metastasis. Targeting this pathway elicits microglia reprogramming toward a proinflammatory phenotype, which enhances antitumor immunity and reduces brain metastatic burden. Furthermore, we found that proinflammatory microglial markers in melanoma brain metastasis are associated with improved responses to immune checkpoint inhibitors in patients and targeting Rela/NF-κB pathway in mice improves responses to these therapies in the brain, suggesting a strategy to enhance antitumor immunity and responses to immune checkpoint inhibitors in patients with melanoma brain metastasis., We thank Angela Nieto for helpful discussions and suggestions along the project and the preparation of the manuscript and AG.de-la-Fuente for advice and assistance, particularly with flow cytometry experiments. We thank the Core Facilities and animal house for the technical support (Verona Villar, Giovanna Exposito, Antonio Caler, Josep Mulet, and Alvaro Fenoll). We thank Prof. Angel Barco for the Relatm1Asba mice, Prof. Larue for the 1014 cells, and the MD Anderson Foundation Biobank. This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, co-financed by ERDF (MICINN-AEI, PID2022-141613OB-I00 [B.S-L.]; PID2021-129053OB-100 [J.P.L-A.]; PID2022-136854OB-I00 [G.M-B.]) and ISCIII (CIBERONC, CB16/12/00295 [G.M-B.]); the FERO Foundation [B.S-L.]; and Melanoma Research Alliance (https://doi.org/10.48050/pc.gr.91574 [B.S-L.]). F.J.R-B. held an GVA-APOSTD21 contract. We also acknowledge support from ICAR and the GEM group [B.S-L.] and the GVA (CIPROM/2021/045 [B.S.-L.] and PROMETEO/2020/007 [J.P.L-A.]), CSIC PTI-NEURO-AGING +, and Centro de Excelencia Severo Ochoa, grant CEX2021-001165-S, funded by MCIN/AEI/10.13039/501100011033. Illustrations were created with BioRender., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A hormetic transcriptional program coregulates invasion, proliferation and dormancy to define metastatic potential

  • Jiménez-Castaño, Raúl
  • Narwade, Nitin
  • Moreno-Bueno, Gema
  • Sánchez-Laorden, Berta
  • Galcerán, Joan
  • Youssef, Khalil Kass
  • Nieto, M. Ángela
Metastasis remains the leading cause of cancer mortality, yet the factors that determine metastatic competence and the timing of its acquisition are not well understood. Using human breast cancer cohorts and multi-omics in preclinical models, here we show that cells exit the primary tumor with pre-set metastatic potential. Integrating spatial transcriptomics with single-cell gene expression and chromatin profiles, we identify the transcription factor Prrx1 as a master regulator of dissemination: beyond its known role in invasion, it represses proliferation by acting on cyclins and cell-cycle inhibitors (Ccnd1/2, Cdkn2a/b/c) and activates a dormancy program (Gas6, Mme, Ogn). Intermediate Prrx1 levels optimize the trade-off between invasion and proliferation/dormancy, producing a hormetic (nonlinear) relationship between Prrx1 expression and metastatic burden. Combined invasion and proliferation signatures strongly stratify breast cancer prognosis, underscoring the clinical relevance of this phenotypic interplay. These findings indicate that metastatic competence emerges from the integration of Prrx1 co-regulated molecular programs, explaining why some invasive cells enter dormancy while others resume growth., The authors thank S. Vega for help and support in managing cell lines and T. M. Gomez, C. López-Blau, and G. Osuna for technical support, and G. Expósito and V. Villar for support at the imaging facility. The authors also thank A. Caler and Pep Mulet for technical help in the FACS/Omics facility. The authors thank Holger Heyn´s team at CNAG (National Center for Genomic Analysis, Barcelona, Spain), especially Sergio Aguilar, Laura Jiménez, and Helena Crowell, for suggestions on scRNA-seq analysis. The authors thank the MD Anderson Foundation Biobank for providing samples (record number B.0000745, Instituto de Salud Carlos III National Biobank). This work was supported by grants MCI PID2021-125682NB-I00 and PID2024-155973NB-I00 to M.A.N., and PID2022-136854OB-I00 to G.M.-B., all funded by MICIU/AEI/10.13039/501100011033 and by FEDER; UE. Funds were also provided by the AECC Scientific Foundation (FC_AECC PRYGN25NIET) and Generalitat Valenciana (Prometeo 2021/45) to M.A.N., and Instituto de Salud Carlos III (CIBERONC, CB16/12/00295) to G.M.-B. M.A.N. also acknowledges financial support from Centro de Excelencia Severo Ochoa, grant CEX2021-001165-S, funded by MCIN/AEI/10.13039/501100011033, and support from the Scientific Network Conexión Cáncer funded by CSIC, Spain. K.K.Y. held an investigator contract from the AECC Scientific Foundation (Ayudas AECC investigador 2022). N.N. is hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union’s Next Generation funds, and R.J.-C. holds a “Severo Ochoa Excellence Programme” PhD contract (PRE2020-091888)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma

  • Zarzuela, Laura
  • López-Cepero, Ignacio G.
  • Rattigan, Kevin M.
  • Reina-Bando, Ana
  • Martín-Montalvo, Jorge
  • Sierra-Párraga, Jesús M.
  • Sánchez-Escabias, Elena
  • Morillo-Huesca, Macarena
  • Oltra, Sara S.
  • Ceballos-Chávez, María
  • Capilla-González, Vivian
  • Moreno-Bueno, Gema
  • Murdoch, Piedad del Socorro
  • Reyes, José C.
  • Helgason, G. Vignir
  • Tomé, Mercedes
  • Durán, Raúl V.
Therapy resistance is a major limitation in therapeutic efficacy for glioblastoma (GBM) patients, positioning GBM among the deadliest tumor types. In this work, we have dissected resistance mechanisms in GBM, which resulted in the identification of FGFR1 pathway as a major controller of the signaling and metabolic rewiring associated to temozolomide (TMZ) resistance. Hence, in FGFR1-positive, p53 WT GBM cells, FGFR1 controls a p53-mediated cell cycle arrest to allow DNA repair in response to TMZ. FGFR1 also regulates a complete metabolic rewiring promoting lipid catabolism and preventing lipid peroxidation. Indeed, FGFR1 inhibition completely abolishes this signaling and metabolic reprograming, restoring sensitivity to TMZ. Our results also indicated a correlation of FGFR1 with poor prognosis in GBM patients, and validated the dual treatment with TMZ and FGFR1 inhibitors as an efficient strategy to induce tumor cell death in FGFR1-positive, p53 WT pre-clinical animal GBM models. These data position FGFR1 as a promising candidate for future clinical evaluation to limit therapy resistance to TMZ in FGFR1-positive GBM patients., Grants PID2021-124251OB-I00 and PID2024-156338OB-I00 funded by the Spanish MICIU/AEI/10.13039/501100011033/and by ERDF/EU (RVD, MTM). Grant RED2022-134927-T funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU (RVD, MTM) Grant PID2023-149538NB-I00 funded by the Spanish MICIU/AEI/10.13039/501100011033/and by ERDF/EU (JCR). Predoctoral FPU contract (FPU19/04914) from the Spanish Ministry of Universities (LZM). Predoctoral contract (PREDOC_00345) funded by PAIDI, Junta de Andalucia (IGLC). Predoctoral FPI contract (PRE2022-101357) funded by Spanish MICIU/AEI/10.13039/501100011033 and FSE+ (ARB). Predoctoral contract (PRDSE258639MART) from Asociación Española Contra el Cáncer (JMM). Grant PI23/00315 funded by Spanish Institute of Health Carlos III, co funded by Fondos FEDER (VCG). Grant CD23/00104 funded by Spanish Institute of Health Carlos III, co funded by Fondos FEDER (JMSP). Grant RyC2023-043933-I funded by Spanish Ministerio de Ciencia, Innovacion y Universidades (VCG). Grant A29754 funded by Cancer Research UK, UK (GVH). Grant CB16/12/00295 funded by Spanish CIBERONC (GMB). Grant PID2022-136854OB-I00 funded by MICIU/AEI/10.13039/501100011033 (GMB)., Peer reviewed